Human G-protein chemokine receptor (CCR5) HDGNR10

Abstract

Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

1 . An isolated polypeptide selected from the group consisting of: 
 (a) a polypeptide comprising an amino acid sequence at least 90% identical to amino acids 1 to 352 of SEQ ID NO:2; and    (b) a polypeptide comprising an amino acid sequence at least 90% identical to amino acids 2 to 352 of SEQ ID NO:2.    
     
     
         2 . The polypeptide of  claim 1 , which comprises an amino acid sequence at least 90% identical to amino acids 1 to 352 of SEQ ID NO:2.  
     
     
         3 . The polypeptide of  claim 2 , which further comprises a heterologous polypeptide.  
     
     
         4 . The polypeptide of  claim 2 , which is glycosylated.  
     
     
         5 . The polypeptide of  claim 2 , which is fused to polyethylene glycol.  
     
     
         6 . A composition comprising the polypeptide of  claim 2  and a pharmaceutically acceptable carrier.  
     
     
         7 . A composition comprising the polypeptide of  claim 3  and a pharmaceutically acceptable carrier.  
     
     
         8 . A composition comprising the polypeptide of  claim 4  and a pharmaceutically acceptable carrier.  
     
     
         9 . A composition comprising the polypeptide of  claim 5  and a pharmaceutically acceptable carrier.  
     
     
         10 . The polypeptide of  claim 1 , which comprises an amino acid sequence at least 90% identical to amino acids 2 to 352 of SEQ ID NO:2.  
     
     
         11 . The polypeptide of  claim 10 , which further comprises a heterologous polypeptide.  
     
     
         12 . The polypeptide of  claim 10 , which is glycosylated.  
     
     
         13 . The polypeptide of  claim 10 , which is fused to polyethylene glycol.  
     
     
         14 . A composition comprising the polypeptide of  claim 10  and a pharmaceutically acceptable carrier.  
     
     
         15 . A composition comprising the polypeptide of  claim 11  and a pharmaceutically acceptable carrier.  
     
     
         16 . A composition comprising the polypeptide of  claim 12  and a pharmaceutically acceptable carrier.  
     
     
         17 . A composition comprising the polypeptide of  claim 13  and a pharmaceutically acceptable carrier.  
     
     
         18 . An isolated polypeptide selected from the group consisting of: 
 (a) a polypeptide comprising an amino acid sequence at least 95% identical to amino acids 1 to 352 of SEQ ID NO:2; and    (b) a polypeptide comprising an amino acid sequence at least 95% identical to amino acids 2 to 352 of SEQ ID NO:2.    
     
     
         19 . The polypeptide of  claim 18 , which comprises an amino acid sequence at least 95% identical to amino acids 1 to 352 of SEQ ID NO:2.  
     
     
         20 . The polypeptide of  claim 19 , which further comprises a heterologous polypeptide.  
     
     
         21 . The polypeptide of  claim 19 , which is glycosylated.  
     
     
         22 . The polypeptide of  claim 19 , which is fused to polyethylene glycol.  
     
     
         23 . A composition comprising the polypeptide of  claim 19  and a pharmaceutically acceptable carrier.  
     
     
         24 . A composition comprising the polypeptide of  claim 20  and a pharmaceutically acceptable carrier.  
     
     
         25 . A composition comprising the polypeptide of  claim 21  and a pharmaceutically acceptable carrier.  
     
     
         26 . A composition comprising the polypeptide of  claim 22  and a pharmaceutically acceptable carrier.  
     
     
         27 . The polypeptide of  claim 18 , which comprises an amino acid sequence at least 95% identical to amino acids 2 to 352 of SEQ ID NO:2.  
     
     
         28 . The polypeptide of  claim 27 , which further comprises a heterologous polypeptide.  
     
     
         29 . The polypeptide of  claim 27 , which is glycosylated.  
     
     
         30 . The polypeptide of  claim 27 , which is fused to polyethylene glycol.  
     
     
         31 . A composition comprising the polypeptide of  claim 27  and a pharmaceutically acceptable carrier.  
     
     
         32 . A composition comprising the polypeptide of  claim 28  and a pharmaceutically acceptable carrier.  
     
     
         33 . A composition comprising the polypeptide of  claim 29  and a pharmaceutically acceptable carrier.  
     
     
         34 . A composition comprising the polypeptide of  claim 30  and a pharmaceutically acceptable carrier.  
     
     
         35 . An isolated polypeptide comprising an amino acid sequence at least 90% identical to the protein sequence encoded by the HDGNR10 coding region in ATCC Deposit No. 97183.  
     
     
         36 . The polypeptide of  claim 35 , which further comprises a heterologous polypeptide.  
     
     
         37 . The polypeptide of  claim 35 , which is glycosylated.  
     
     
         38 . The polypeptide of  claim 35 , which is fused to polyethylene glycol.  
     
     
         39 . A composition comprising the polypeptide of  claim 35  and a pharmaceutically acceptable carrier.  
     
     
         40 . A composition comprising the polypeptide of  claim 36  and a pharmaceutically acceptable carrier.  
     
     
         41 . A composition comprising the polypeptide of  claim 37  and a pharmaceutically acceptable carrier.  
     
     
         42 . A composition comprising the polypeptide of  claim 38  and a pharmaceutically acceptable carrier.  
     
     
         43 . An isolated polypeptide comprising an amino acid sequence at least 95% identical to the protein sequence encoded by the HDGNR10 coding region in ATCC Deposit No. 97183.  
     
     
         44 . The polypeptide of  claim 43 , which further comprises a heterologous polypeptide.  
     
     
         45 . The polypeptide of  claim 43 , which is glycosylated.  
     
     
         46 . The polypeptide of  claim 43 , which is fused to polyethylene glycol.  
     
     
         47 . A composition comprising the polypeptide of  claim 43  and a pharmaceutically acceptable carrier.  
     
     
         48 . A composition comprising the polypeptide of  claim 44  and a pharmaceutically acceptable carrier.  
     
     
         49 . A composition comprising the polypeptide of  claim 45  and a pharmaceutically acceptable carrier.  
     
     
         50 . A composition comprising the polypeptide of  claim 46  and a pharmaceutically acceptable carrier.